Futura Genetics

futuragenetics.com

Futura Genetics are pioneers in the field of wellness and health with groundbreaking genomic tests that help people around the world to prevent illness and conditions using simple lifestyle changes based on personal self-knowledge about DNA.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

AI

BIOMARIN AND DEEP GENOMICS TO COLLABORATE ON ADVANCING PROGRAMS IDENTIFIED USING ARTIFICIAL INTELLIGENCE

BioMarin | November 18, 2020

news image

BioMarin Pharmaceutical Inc. and Deep Genomics declares that the organizations have gone into a preclinical collaboration that will use Deep Genomics' artificial intelligence drug discovery platform (The AI Workbench) to distinguish oligonucleotide drug applicants in four uncommon sickness signs with high neglected need. Deep Genomics will get an undisclosed forthright installment and is qualified to get improvement achievements as a piece of the coordinated effort. BioMarin will get an elit...

Read More

Industrial Impact

PROPHASE LABS TO ANNOUNCE FORMATION OF A SUBSIDIARY PROPHASE BIOPHARMA, INC.

ProPhase Labs, Inc. | June 29, 2022

news image

ProPhase Labs, Inc., a diversified biotech, genomics, and diagnostics company manufacturing homeopathic and health products, announced the formation of a new wholly-owned subsidiary, ProPhase BioPharma, Inc. (PBIO), for the development and licensing of new therapeutic compounds, drugs, and biotechnology. The subsidiary will be focused on advancements in technology across the biochemical industry and creating and developing new solutions that can transform the outcomes of healthcare.
Read More

Industrial Impact

NAVERIS INC. RAISES $51 MILLION TO ADVANCE COMMERCIALIZATION OF NAVDX

Naveris, Inc. | September 20, 2022

news image

Naveris, Inc., a commercial-stage life sciences company dedicated to improving patient care through earlier detection of viral-driven cancers, today announced a $33.4 million expansion of its Series A financing, bringing the total investment in Naveris to $51 million. The financing was led by Gurnet Point Capital, joined by TechU Ventures and BrightEdge, the impact and venture capital arm of the American Cancer Society. Naveris’ blood tests for earlier cancer detection use p...

Read More

Industrial Impact

PICTOR ANNOUNCES FUNDING ROUND AFTER SUCCESSFUL LAUNCH IN NEW ZEALAND AND USA OF SARS-COV-2 ANTIBODY TEST

Pictor | December 05, 2022

news image

Pictor, a global leader in immunodiagnostics announced a funding round to help accelerate pipeline product development projects along with market development activities within Australia/New Zealand, the US and Europe for its Human Health and Animal Health portfolios. This follows the recent successful launch of the PictArray™ SARS-CoV-2 IgG Antibody Test through Rako Science in New Zealand and key partners in the US. “The test better informs patients and doctors in det...

Read More
news image

AI

BIOMARIN AND DEEP GENOMICS TO COLLABORATE ON ADVANCING PROGRAMS IDENTIFIED USING ARTIFICIAL INTELLIGENCE

BioMarin | November 18, 2020

BioMarin Pharmaceutical Inc. and Deep Genomics declares that the organizations have gone into a preclinical collaboration that will use Deep Genomics' artificial intelligence drug discovery platform (The AI Workbench) to distinguish oligonucleotide drug applicants in four uncommon sickness signs with high neglected need. Deep Genomics will get an undisclosed forthright installment and is qualified to get improvement achievements as a piece of the coordinated effort. BioMarin will get an elit...

Read More
news image

Industrial Impact

PROPHASE LABS TO ANNOUNCE FORMATION OF A SUBSIDIARY PROPHASE BIOPHARMA, INC.

ProPhase Labs, Inc. | June 29, 2022

ProPhase Labs, Inc., a diversified biotech, genomics, and diagnostics company manufacturing homeopathic and health products, announced the formation of a new wholly-owned subsidiary, ProPhase BioPharma, Inc. (PBIO), for the development and licensing of new therapeutic compounds, drugs, and biotechnology. The subsidiary will be focused on advancements in technology across the biochemical industry and creating and developing new solutions that can transform the outcomes of healthcare.
Read More

news image

Industrial Impact

NAVERIS INC. RAISES $51 MILLION TO ADVANCE COMMERCIALIZATION OF NAVDX

Naveris, Inc. | September 20, 2022

Naveris, Inc., a commercial-stage life sciences company dedicated to improving patient care through earlier detection of viral-driven cancers, today announced a $33.4 million expansion of its Series A financing, bringing the total investment in Naveris to $51 million. The financing was led by Gurnet Point Capital, joined by TechU Ventures and BrightEdge, the impact and venture capital arm of the American Cancer Society. Naveris’ blood tests for earlier cancer detection use p...

Read More
news image

Industrial Impact

PICTOR ANNOUNCES FUNDING ROUND AFTER SUCCESSFUL LAUNCH IN NEW ZEALAND AND USA OF SARS-COV-2 ANTIBODY TEST

Pictor | December 05, 2022

Pictor, a global leader in immunodiagnostics announced a funding round to help accelerate pipeline product development projects along with market development activities within Australia/New Zealand, the US and Europe for its Human Health and Animal Health portfolios. This follows the recent successful launch of the PictArray™ SARS-CoV-2 IgG Antibody Test through Rako Science in New Zealand and key partners in the US. “The test better informs patients and doctors in det...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us